Why is Eldepryl (rivastigmine) in the news about CMS pricing pressure?
Eldepryl is a cholinesterase inhibitor prescribed for Parkinson’s disease dementia. Because its active ingredient is off‑patent, several generic versions compete for market share. However, Medicare Part D formulary decisions and CMS’s cost‑control initiatives can still influence the drug’s reimbursement level. CMS evaluates drugs based on therapeutic benefit, cost‑effectiveness, and budget impact, which has led to tighter scrutiny of rivastigmine’s pricing and formulary placement. [1]
How does CMS’s Part D coverage affect patients on Eldepryl?
Under Part D, CMS sets a coverage gap (“donut hole”) that can increase out‑of‑pocket costs for patients if the drug’s cost is high relative to the plan’s formulary tier. Recent CMS guidance encourages manufacturers to offer tiered pricing or discount programs to keep the drug in a lower formulary tier, thereby reducing patient burden. Eldepryl’s manufacturer has responded by negotiating rebates and encouraging use of lower‑cost generics. [1]
What alternatives exist for Parkinson’s disease dementia, and how do they compare on CMS pricing?
Other cholinesterase inhibitors—donepezil and galantamine—are also used for Parkinson’s dementia. Medicare formulary decisions consider comparative efficacy and cost; generics of these drugs are widely available and typically cheaper than brand‑name rivastigmine. Because of this, CMS tends to favor lower‑priced alternatives, placing Eldepryl higher on the formulary ladder unless it demonstrates superior clinical benefit. [2]
When is the next potential pricing shift expected for Eldepryl?
CMS periodically reviews drug pricing as part of its annual Part D formulary update. The most recent review in 2023 resulted in a modest price adjustment for the generic form of rivastigmine, and another review is scheduled for the 2025 formulary cycle. Any significant price change will likely stem from negotiations tied to CMS’s new value‑based contracting model. [2]
Can biosimilars or new generics enter the market before pricing changes?
Because the active ingredient is no longer patented, generics have already been approved for rivastigmine. Future generic entrants can lower prices further if they offer a lower cost of goods. CMS encourages such competition through its “generic substitution” policies, which can lead to automatic price reductions when a new generic appears. [1]
What risks does the manufacturer face if pricing pressure continues?
If CMS maintains a high reimbursement tier or increases the required rebate percentage, the manufacturer may see reduced revenue per prescription. This could prompt the company to delay new product launches or reduce marketing spend on the Parkinson’s indication, potentially affecting innovation. The manufacturer also risks losing market share to generic competitors, which could accelerate the drug’s decline in clinical use. [2]
How does the 340B program intersect with Eldepryl pricing?
Hospitals that participate in the 340B drug discount program purchase medications at reduced prices, including Eldepryl. CMS monitors 340B utilization to prevent over‑billing, and if a drug’s pricing is deemed excessive, CMS can audit or limit 340B purchases. Thus, high pricing can lead to tighter scrutiny for both the manufacturer and participating hospitals. [1]
What does the patent status look like for Eldepryl’s active ingredient?
Rivastigmine’s original patents expired long ago, so the drug is in the generic era. There are no current patent extensions covering the brand‑name formulation, which removes patent‑based price protection and makes the product more vulnerable to market forces. [3]
When can patients expect the most cost savings on Eldepryl?
The most significant savings are likely when CMS lowers the drug’s formulary tier or the manufacturer offers a new discount program. Patients can also benefit by switching to a generic formulation, which is already available and typically costs 70–90 % less than the brand name. Monitoring Medicare Part D updates can help patients anticipate upcoming price changes. [2]
Sources
[1] https://www.drugpatentwatch.com/brands/eldepryl
[2] https://www.drugpatentwatch.com/coverage/medicare-pdp
[3] https://www.drugpatentwatch.com/patents/withdrawal/7480/